Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 82 for “"B-cell lymphoma"”.
-
Automated Analysis of Flow Cytometry Data for B-Cell Lymphoma
… of hematolymphoid malignancies including B-cell lymphomas, is an innovative technique that measures the fluorescence of suspended cells. Traditionally, the method of evaluating the research and clinical study of flow cytometry data is done by the process of manual gating along with a review …
-
Hdm2 Small-Molecule Inhibitors For Therapeutic Intervention In B-Cell Lymphoma
<p>Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, compromising p53 activity. Therefore, lymphoma is a suitable model for studying therapeutic value of disrupting HDM2-p53 association by small-molecule inhibitors (SMIs). HDM2 SMIs have been developed and are currently …
-
Functional Drivers of Therapeutic Response in Diffuse Large B Cell Lymphoma
<p>Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma and a leading cause of death among B cell lymphomas. The disease displays a remarkable amount of genetic and clinical heterogeneity, hampering efforts at designing effective therapeutic agents. The last major …
-
Genetic Subclones Identify Phenotypic Variation in Diffuse Large B-Cell Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma. Many efforts have characterised DLBCL subtypes that account for some of the heterogeneity in clinical outcome following standard therapy. However, not much is known regarding intratumoural heterogeneity. Case …
-
Targeting the B-Cell Receptor in Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive malignancy of which one-third of diagnosed patients ultimately die. New treatment paradigms for relapsedrefractory patients are needed. Almost all DLBCL tumours express a B-cell receptor (BCR), which is a cell surface antigen receptor of …
-
Molecular Characterisation of Diffuse Large B-cell Lymphoma in South Africa
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous and aggressive disease and is the most common subtype of non-Hodgkin lymphoma (NHL) in adults. Additionally, this subtype of lymphoma is also the most common in people infected with the Human Immunodeficiency virus (HIV), and the …
-
Targeting Epigenetic Regulators For The Treatment of Diffuse Large B-Cell Lymphoma
… promise for the treatment of Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL). Compared to a 60% Objective Response Rate (ORR) in Phase I clinical trials, Phase II trial results for the EZH2 inhibitor EPZ-6438 reported an attenuation of response. Mechanisms contributing to …
-
Pim Kinase Inhibition: Single Agent and Combination Approaches In B-Cell Lymphoma
… kinases are Ser/Thr/Tyr kinases. They modulate B-cell development but become oncoproteins and promote cancer development once overexpressed. Containing three isoforms, Pim-1, -2 and -3 are known to phosphorylate various substrates that regulate transcription, translation, cell cycle, and survival …
-
Elucidating Targetable Genetic Vulnerabilities in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most prevalent form of non-Hodgkin lymphoma is marked by significant heterogeneity in its morphology, genetic irregularities, and clinical behavior. Current prognostic tools, including the International Prognostic Index and cell-of-origin transcriptional …
-
Prognostic Markers and Mechanisms of Chemotherapy Resistance in Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease. Identification of prognostic and predictive markers is important to design individualised and effective treatment strategies. This thesis describes different approaches to search for molecular prognostic markers and …
-
The biological effects of HIV-1 Nef on the development of B-cell Lymphoma
… compared to the rest of the world. Burkitt lymphoma (BL) is an extremely aggressive cancer that is considered to be a highly prevalent subtype of Non-Hodgkin Lymphoma (NHL) affiliated with chronic HIV infection. While the immunosuppressive aspect of HIV remains a primary cause for the …
-
The Role of Pag1 In The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma
<p>Diffuse Large B Cell Lymphoma (DLBCL) is the most common aggressive hematologic malignancy in adults, but despite recent advances in treatment, many patients today still face poor outcomes. Of the two types of DLBCL, activated B-cell (ABC) and germinal center B-cell (GCB), patients diagnosed …
-
Combined Inhibition of SREBP and m-TORC1 Signaling Synergistically Inhibits the Proliferation of B Cell Lymphoma
… role in maintaining sterol homeostasis during B cell activation and the proliferation of germinal center B cells. It is unclear whether this pathway can be targeted to effectively treat B cell lymphoma. We discovered that inhibiting SREBP signaling or its downstream target HMG-CoA reductase …
-
Detection of Cell-free Tumor DNA in Liquid Biopsies of Dogs with B cell Lymphoma: A Biomarker Discovery
Lymphoma is a common hematopoietic malignancy in canines. Current diagnostic techniques to diagnose lymphoma are often invasive and expensive. Additionally, tumor heterogeneity complicates the accurate classification and diagnosis of specific subtypes, hindering the development of targeted therapy …
-
Programmed cell death-ligand 1 (PD-L1) expression in HIV-associated diffuse large B-cell lymphoma – role and regulation
Diffuse Large B cell Lymphoma (DLBCL) is an aggressive disease that displays striking heterogeneity at both the molecular and clinical levels; and as a result, up to 40% of patients relapse or are refractory to standard first-line therapy. DLBCL is the most common subtype of lymphoma affecting …
-
Expression levels of miRNA-127 in a cohort of HIV-positive and HIV-negative Diffuse Large B-Cell Lymphoma.
Diffuse Large B Cell Lymphoma is one of the most common Non-Hodgkin’s Lymphomas. It is prevalent in older age patients but as of late there has been a rise in the younger population in South Africa due to the rise of HIV. DLBCL is quite an aggressive cancer but can be treated, however the relapse …
-
Review of Diffuse large B cell lymphoma, pharmacological aspects of treatment and comparison of outcome between Pre-,Post Rituximab era
Diffuse large B Cell lymphoma (DLBCL) is a type aggressive non-Hodgkin Lymphoma (NHL). About 30% of patients who diagnosed NHL is DLBCL in both male and female. It is divided into 3 major types which distinct by immunological characteristics. It shall shows variable spectrum of prognosis and …
-
An investigation of the impact of the B cell lymphoma factor Activation Induced Cytidine Deaminase (AICDA/AID) on epigenetic plasticity
… linked to cancer progression, particularly B-cell derived non-Hodgkin lymphomas, but has also been associated with other inflammation-associated cancers, including colorectal cancer (CRC). The widely recognised normal role of AICDA is in antibody-producing B cells, where its cytosine …
Page 1 of 5